Mepolizumab, quality of life, and severe eosinophilic asthma.
It is now ten years since the publication of the first clinical trial, eight years since the first key proof of concept studies in a population selected on the basis of inflammatory pattern and two years since approval of Mepolizumab as a treatment for severe eosinophilic asthma. In some countries t...
| 主要作者: | |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
Elsevier
2017
|